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We described the rapid production of the domain III (DIII) of the envelope (E) protein in plants as a vaccine candidate forWest Nile
Virus (WNV). Using various combinations of vector modules of a deconstructed viral vector expression system, DIII was produced
in three subcellular compartments in leaves ofNicotiana benthamiana by transient expression. DIII expressed at much higher levels
when targeted to the endoplasmic reticulum (ER) than that targeted to the chloroplast or the cytosol, with accumulation level up
to 73 𝜇g DIII per gram of leaf fresh weight within 4 days after infiltration. Plant ER-derived DIII was soluble and readily purified
to > 95% homogeneity without the time-consuming process of denaturing and refolding. Further analysis revealed that plant-
produced DIII was processed properly and demonstrated specific binding to an anti-DIII monoclonal antibody that recognizes
a conformational epitope. Furthermore, subcutaneous immunization of mice with 5 and 25 𝜇g of purified DIII elicited a potent
systemic response.This study provided the proof of principle for rapidly producing immunogenic vaccine candidates againstWNV
in plants with low cost and scalability.
1. Introduction
West Nile Virus (WNV) belongs to the Flavivirus genus of
the Flaviviridae family. It is a positive-stranded, enveloped
RNA virus that infects the central nervous system (CNS) of
humans and animals. Once a disease that was restricted to
OldWorld countries, it entered into the Western hemisphere
through New York City in 1999 and has now spread across
the United States (US), Canada, the Caribbean region, and
Latin America [1]. The outbreaks of WNV have become
more frequent and severe in recent years with 2012 as the
deadliest yet with 286 fatalities in the US [1]. WNV infection
causes fever that can progress to life-threatening neurolog-
ical diseases. The most vulnerable human population for
developing encephalitis, meningitis, long-term morbidity,
and death includes the elderly and immunocompromised
individuals [2]. Recent studies also identified genetic factors
associated with susceptibility to the disease [3, 4]. Currently,
no vaccine or therapeutic agent has been approved for human
application.The threat of globalWNVepidemics and the lack
of effective treatment warrant the development of vaccines
and production platforms that can quickly bring them to
market at low cost.
TheWNVEnvelope (E) glycoproteinmediates viral bind-
ing to cellular receptors and is essential for the subsequent
membrane fusion [5]. It is also amajor target of host antibody
responses [5]. Studies have shown that WNV E shares a
three-domain architecture with E proteins of dengue and
tick-borne encephalitis viruses [6]. The domain III (DIII) of
WNVE protein contains the cellular receptor-bindingmotifs
and, importantly, the majority of the neutralizing epitopes
that induce strong host antibody responses and/or protective
immunity are mapped to this domain [7]. As a result, DIII
has been targeted as a WNV vaccine candidate [8]. Insect
cell and bacterial cultures have been explored to express the
WNV DIII protein [9, 10]. However, these culture systems
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are challenged by their limited scalability for large-scale
protein production. Moreover, DIII expression in bacterial
cultures often leads to the formation of inclusion bodies,
which requires a cumbersome solubilization and refolding
process to yield a recombinant DIII protein that resembles its
native structure [10].
Expression systems based on plants may provide solu-
tions to overcome these challenges, because they provide
highly scalable production of recombinant proteins at low
cost and have a low risk of introducing adventitious human or
animal viruses or prions [11, 12]. Stable transgenic plants were
first explored to produce subunit vaccine proteins. While
feasible, the low protein yield and the long time period are
required for generating and selecting transgenic lines hinder
a broad application of this strategy [13]. Recently, transient
expression systems based on plant virus have been developed
to address these challenges. While the infectivity of plant
viruses has been eliminated through viral “deconstruction,”
these vectors still retain the robustness of the original plant
virus in replication, transcription, or translation [14]. Thus,
deconstructed plant viral vectors promote high-level produc-
tion of recombinant protein within 1 to 2 weeks of vector
delivery [14–16].TheMagnICONsystem is a popular example
of these vectors based on in planta assembly of replication-
competent tobacco mosaic virus (TMV) and potato virus
X (PVX) genomes from separate provector cDNA modules
[17, 18]. The 5󸀠 module carries the viral RNA dependent
RNA polymerase and themovement protein (MP), and the 3󸀠
module contains the transgene and the 3󸀠 untranslated region
(UTR). A. tumefaciens strains harboring the twomodules are
mixed together and coinfiltrated into plant cells along with
a third construct that produces a recombination integrase.
Once expressed, the integrase assembles the 5󸀠 and 3󸀠modules
into a replication-competent TMV or PVX genome under
the control of a plant promoter [18, 19]. This assembled
DNA construct is then transcribed and spliced to generate a
functional infective replicon. Geminiviral expression system
is another example: a DNA replicon system derived from
the bean yellow dwarf virus (BeYDV) [20, 21]. Another
interesting example is an expression vector system that
is based on the 5󸀠 and 3󸀠-untranslated region of Cowpea
mosaic virus (CPMV) RNA-2. This vector system does not
require viral replication yet allows high-level accumulation
of recombinant proteins in plants [22]. Thus, these plant
transient expression systems combine the advantages of
speed and flexibility of bacterial expression systems and
the post-translational protein modification capability and
high-yield of mammalian cell cultures. As a result of this
development, a variety of protein vaccine candidates have
been produced in plants [11, 12, 23–26]. The immunogenicity
of a plant-produced vaccine candidate against WNV has not
been described.
Here, we described the rapid production of the WNV
DIII in Nicotiana benthamiana plants using the TMV-based
vectors of theMagnICON system.Wedemonstrated thatDIII
can be expressed in three subcellular compartments of the
plant cell including endoplasmic reticulum (ER), chloroplast,
and cytosol, with the highest accumulation level in ER within
4 days after infiltration. Plant ER-derived DIII was soluble
and was readily purified to >95% homogeneity. Further anal-
ysis revealed that plant-produced DIII was folded properly as
it exhibited specific binding to a monoclonal antibody that
recognizes a large conformational epitope on WNV DIII.
The immunogenicity of plant-derivedDIII was demonstrated
in mice as subcutaneous immunization elicited a potent
systemic response.
2. Results
2.1. Expression of WNV E DIII in ER, Chloroplast, and Cytosol
of N. benthamiana Leaves. To demonstrate the feasibility of
using plants to produce a candidate vaccine forWNV, we first
determined what subcellular compartment was optimal for
DIII accumulation. Agrobacterium tumefaciens strain con-
taining the 3󸀠 DIII construct module was codelivered into N.
benthamiana leaves alongwith the 5󸀠module and an integrase
construct through agroinfiltration [27, 28]. Three different
5󸀠 modules were specifically chosen to target DIII into ER,
chloroplast, or the cytosol [24]. Leaf necrosis was observed in
the infiltrated area 4 or 5 days post infiltration (dpi) in plants
for all constructs, with cytosol-targeted construct causing the
most severe symptoms (data not shown). By 6 dpi, necrosis
was too extensive to recover significant amounts of live tissue
from the infiltrated leaf area. As a result, DIII expression was
examined between 2 and 5 dpi by Western blotting. For the
construct targeted to accumulate DIII in ER, a positive band
with the predicted molecular weight for DIII (13.5 kDa) was
detected on Western blot starting 3 dpi (Figure 1, Lanes 3–5).
In contrast, no positive band was detected for chloroplast or
cytosol-targeted DIII construct even on 5 dpi (Figure 1, Lanes
6 and 7). An E. coli-produced DIII was used as a positive
control and, as expected, it was detected as a positive band
on the Western blot (Figure 1, Lane 8). The E. coli-produced
DIII appeared to be larger than that from plants (16.9 kDa),
because it contained multiple polypeptide tags from the
bacterial expression vector pET28a (EMD Milipore). The
lack of positive band in the negative control leaf samples
(Figure 1, Lane 1) confirmed the specificity of the DIII band.
The expression of DIII was quantified by a sandwich ELISA
using two WNV specific antibodies (Figure 2). In leaves that
DIII was targeted to the cytosol or chloroplast, the maximal
levels of accumulation are below 1.16 𝜇g of DIII per gram
of leaf fresh weight (LFW) or 0.01% of total soluble protein
(TSP), confirming the result of Western blotting. The ER-
targeted DIII reached the highest level of production at 4 dpi,
with an average accumulation of 73𝜇g/g LFW or 0.63%
TSP, approximately ∼63 times more than that in cytosol or
chloroplast (Figure 2).
2.2. Purification of DIII from N. benthamiana Plants. The
availability of an efficient purification scheme is another
essential component for plant-derived DIII to become a
viable WNV vaccine candidate. Since DIII was tagged with
a His
6
tag, we developed a two-step purification proce-
dure based on acid precipitation and immobilized metal
ion affinity chromatography (IMAC). Samples from various
purification steps were analyzed by Coomassie blue staining
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Figure 1: Western blot analysis of DIII expression in N. benthami-
ana. DIII was extracted from N. benthamiana leaves and separated
on 15% SDS-PAGE gels and blotted onto PVDF membranes. MAb
hE16 and a goat anti-human kappa chain antibody were incubated
with the membranes sequentially to detect DIII. Lane 1: protein
sample extracted from uninfiltrated leaves as a negative control;
Lanes 2–5: sample collected 2, 3, 4, and 5 dpi from leaves infiltrated
with ER-targetedDIII construct; Lane 6: sample collected 5 dpi from
leaves infiltrated with chloroplast-targeted DIII construct; Lane 7:
sample collected 5 dpi from cytosol-targeted DIII leaves; Lane 8: E.
coli-produced DIII as a positive control.
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Figure 2: Temporal expression patterns of DIII in chloroplast,
cytosol, and ER. Total protein from plant leaves infiltrated with
chloroplast, cytosol, or ER-targeted DIII construct was extracted
on 2–5 dpi and analyzed by an ELISA with mAb hE16 which
recognizes a conformational epitope on DIII and a polyclonal anti-
DIII antibody. Mean ± SD of samples from several independent
experiments are presented.
analysis of SDS-PAGE (Figure 3(a)) andWestern blot analysis
(Figure 3(b)). Interestingly, DIII was efficiently extracted in
the soluble protein fraction of plant leaves (Figures 3(a) and
3(b), Lane 2), in contrast to the insoluble inclusion body in
E. coli [29]. Precipitation with low pH (5.0) removed a large
proportion of endogenous plant proteins including the most
abundant host protein, the photosynthetic enzyme RuBisCo
(Figure 3(a), Lane 1), while leaving DIII in the supernatant
(Figure 3(b), Lanes 1 and 3). The pH adjustment from pH
5.0 to pH 8.0, which was required for the binding of DIII
to the nickel (Ni) IMAC resin, did not cause any significant
change in protein profile (Figures 3(a) and 3(b), Lane 4). Ni
IMAC efficiently removed the remaining plant host proteins
(Figure 3(a), Lanes 5 and 6) and enriched DIII to greater than
95% purity (Figures 3(a) and 3(b), Lane 7). A faint reactive
band was detectable in fractions of total soluble protein, pH
5.0 precipitation, and IMAC flow through (Figure 3(b), Lanes
2–5), suggesting a minor DIII degradation product. Only
the intact DIII band with the predicted molecular mass was
detected in the purified DIII fraction. Approximately 3.2mg
of purified DIII was obtained from 100 g LFW. These results
demonstrated that not only can DIII be rapidly produced in
plants, but also isolated and purified to high homogeneity
using a scalable purification method.
2.3. Plant-Derived DIII Is Specifically Recognized by a Neu-
tralizing Monoclonal Antibody against WNV DIII. To estab-
lish a similarity of structural and immunological proper-
ties between plant-produced and the native viral DIII, we
examined the binding of plant-derived DIII to a monoclonal
antibody (mAb) hE16 generated against WNV E. Our pre-
vious studies have shown that hE16 not only had potent
neutralizing activity, but it also effectively protected mice
from a lethal infection of WNV in both prophylactic and
postexposure models [30, 31]. Since hE16 binds a confor-
mational epitope that consists of 4 discontinuous secondary
structural elements of the nativeWNVDIII [32], recognition
of a recombinant DIII by hE16 will be informative of its
proper folding. ELISA results showed that plant-produced
DIII demonstrated specific binding to hE16 produced in
mammalian cell culture (Figure 4). DIII also specifically
bound to a plant-derived hE16 that showed potent thera-
peutic efficacy in mice (Figure 4) [30]. Similar results were
obtainedwith the sandwich ELISAused for the quantification
of DIII in plant extracts (data not shown). These results
indicate that plant-produced DIII was folded into a tertiary
structure that resembled the native viral DIII on the surface
of WNV.
2.4. Plant-Produced DIII Elicits Potent Systemic Immune
Response in Mice. To evaluate the immunogenicity of plant-
derived DIII, BALB/c mice were injected subcutaneously
with four doses of DIII over an 8-week time period (on
days 0, 21, 42, and 63). Two dosages of 5𝜇g and 25 𝜇g of
DIII were tested with alum as adjuvant. Mice were divided
into 5 groups (𝑛 = 6 per group), with group 1 as the
negative control group injected with alum + saline (PBS),
groups 2 and 3 with plant-derived DIII, and groups 4 and
5 with E. coli-produced DIII as a control. Individual serum
DIII-specific antibody responses were measured by ELISA
and Geometric mean titer (GMT) was calculated for each
group at various time points (Figure 5). Samples collected
from the control PBS group throughout the entire experiment
course and preimmune sera for all groups taken prior to the
first immunization (day 0) were negative for the presence
of anti-DIII IgG (titer < 10) (Figure 5). All mice in groups
immunized with 25 𝜇g of DIII responded after the first
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Figure 3: Purification of DIII from N. benthamiana leaves. DIII was purified from leaves infiltrated with ER-targeted DIII construct and
analyzed on 15% SDS-PAGE gels and either visualized with Coomassie blue stain (a) or transferred to a PVDF membranes followed by
Western analysis with hE16 (b). Lane 1: pH 5.0 precipitation pellet; Lane 2: total extracted protein; Lane 3: pH 5.0 supernatant; Lane 4: Ni
IMAC loading; Lane 5:Ni IMACflow through; Lane 6:Ni IMACwash; Lane 7:Ni IMACelute; Lane 8:E. coli-producedDIII; Lane 9:molecular
weight marker.
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Figure 4: Specific binding ELISA of hE16 to plant-derived DIII.
Serial dilutions of hE16 purified from mammalian or plant cells
were incubated in sample wells coated with plant-produced WNV
DIII and detected with an HRP-conjugated anti-human gamma
antibody. A commercial generic human IgG was used as a negative
control. Mean ± SD of samples from three independent experiments
is presented.
administration, while a response was only detectable after
the third DIII delivery for mice immunized with the lower
dosage (5 𝜇g). This dose-dependent trend was also reflected
in the amplitude of the response throughout the various time
points of the immunization. For groups receiving DIII, IgG
titers increased after each of the first three antigen’s delivery
and reached its peak at week 8, two weeks after the third
immunization. Antibody titers at week 11 (two weeks after the
fourth dose) were similar to those of week 8 for all groups
except the 5 𝜇g E. coli-DIII group (Figure 5). This indicated
that the last immunization did not significantly further boost
the DIII-specific antibody response, especially in mice that
received the higher dosage of DIII. Compared with E. coli-
produced DIII, plant-derived DIII showed at least equivalent
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Figure 5: Time course of DIII specific antibody responses in mice
upon subcutaneous delivery of plant-derived DIII. BALB/C mice
(𝑛 = 6 per group) were injected on weeks 0, 3, 6, and 9 with the
indicated dosage of antigen. Blood samples were collected on the
indicated weeks and serum IgG was measured by ELISA.The 𝑦-axis
shows the geometric means titers (GMT) and the error bars show
the 95% level of confidence of the mean.
potency (𝑃 > 0.5) in eliciting humoral response againstWNV
(Figure 5).
In order to evaluate the Th type of response induced
by DIII, antigen-specific IgG subtypes IgG1 and IgG2a were
evaluated by ELISA for samples collected at week 11 from
mice that were immunized with 25 𝜇g of E. coli- or plant-
derived DIII. As shown in Table 1, >99% of DIII-specific IgG
belonged to the IgG1 subtype, indicating an overwhelmingly
Th2-type response stimulated by DIII antigen with alum as
the adjuvant.
2.5. Characterization of Antiserum against Plant-Derived DIII
Antigen. Antisera obtained at week 11 frommice of the 25 𝜇g
plant-DIII groupwere examined in a binding assay with yeast
that displayed DIII in its native conformation on its surface.
Flow cytometric analysis demonstrated that antibodies in
BioMed Research International 5
Table 1: Anti-DIII IgG subtypes (IgG1 and IgG2a) of pooled serum samples.
Group 3 Group 5
Concentration (𝜇g/mL) SEM Subtype/total % Concentration (𝜇g/mL) SEM Subtype/total %
IgG1 506.33 58.00 99.5% 488.00 48.08 99.8%
IgG2a 2.67 0.70 0.5% 0.98 0.44 0.2%
Serum samples collected at week 11 were pooled for each indicated group and analyzed by ELISA for IgG1 and IgG2a antibody concentration. Mean
concentration (𝜇g/mL) of the IgG subtype and the standard error of the mean (SEM) from several independent measurements are presented. Group 3: mice
received 25 𝜇g per dosage of plant-derived DIII; Group 5: mice received 25 𝜇g per dosage of E. coli-derived DIII.
the anti-DIII sera displayed positive binding to DIII on the
surface of the yeast (Figure 6(a)). This indicated that anti-
DIII sera contained antibodies that can recognize the native
viral DIII protein. Similar positive binding was observed
for positive control mAb hE16 (Figure 6(c)), but not for
equivalent antisera frommice that were immunized with PBS
(Figure 6(b)). To investigate if plant-DIII elicited antibodies
that bind to the same epitope as the protective mAb hE16,
antisera were further analyzed with a competitive ELISA.
Results showed that preincubation of DIII with antisera from
immunization of plant-derived DIII significantly inhibited
its binding to hE16 (Figure 7). No reduction in DIII bind-
ing to hE16 was observed when it was preincubated with
preimmune serum. This indicated that plant-produced DIII
induced the production of anti-DIII IgGs that bind to the
sameprotective epitope as hE16 or at least to epitopes adjacent
to that one.This suggested some of the antibodies in the anti-
DIII sera were potentially neutralizing and protective.
3. Discussion
WNV has caused continuous outbreaks in the US since its
introduction in 1999. While the number of cases fluctuated
and even dropped from 2008 to 2011, the illusion that its
transmission would remain at a low rate quickly evaporated
as a largeWNV epidemic with high incidence of neurological
disease broke out in 2012. WNV was also reported to expand
into new geographic areas in Europe and other parts of
the world. Therefore, the world may face larger and more
severeWNVoutbreaks associatedwith humanmorbidity and
mortality. In the absence of an effective treatment, the need
for an effective WNV vaccine is more urgent than ever to
halt its expansion and to protect human populations that are
vulnerable for developing neurological complications.
Previous studies showed that immunization of DIII
produced in E. coli or insect cell cultures with CpG
oligodeoxynucleotide adjuvant or in fusion with bacterial
flagellin elicited WNV-neutralizing antibodies in mice and,
in certain instances, protected mice from WNV infection
[29, 33, 34]. While encouraging, these expression systems
may not be able to provide the scale and robustness for
WNVmanufacturing, as the global threat ofWNV epidemics
demands a scalable production platform that can quickly
produce large quantities of vaccines at low cost. Moreover,
DIII is often recovered in the insoluble inclusion bodies
in bacterial cultures, thus requiring a cumbersome solubi-
lization and refolding process to yield DIII proteins that
resemble their native conformation [29]. The high level of
endotoxins in E. coli-based expression system also raises
biosafety concerns and demands an expensive process of
purification and validation for their removal to ensure the
safety of the final product [10].
Here, we demonstrated that a transient plant expression
system provided a rapid production of WNV DIII in N. ben-
thamiana plants. In contrast to forming insoluble aggregates
in E. coli cultures, DIII was produced as a soluble protein
in plant cells. As a result, it can be directly extracted and
purified to >95% homogeneity by a simple and a scalable
purification scheme without the time-consuming process of
denaturing and refolding. This enhanced the likelihood of
producing DIII protein that displays its native conformation.
Indeed, plant-derived DIII appeared to fold properly as it was
specifically recognized by hE16, a protective anti-WNVmAb
that binds a large conformational epitope spanning 4 distinct
regions of DIII.
Within the three subcellular compartments we tested,
DIII accumulated at much higher levels in ER than in
chloroplast and cytosol. The highest expression level was
achieved rapidly at 4 dpi, with an average accumulation of
approximately 73𝜇g/g LFW. This level is lower than that of
other pharmaceutical proteins we have produced with the
MagnICON system [24, 30, 35].The induction of leaf necrosis
by DIII may contribute to the lower expression level as it
may shorten the window for accumulation. It is not clear if
the observed leaf necrosis is caused by an inherent toxicity
of DIII or by the employed overexpression system. To our
best knowledge,WNVDIII has not been produced in another
plant species orwith another plant expression system.We also
speculate that the 73𝜇g/g LFW was a conservative estimate
from the early small-scale expression experiments, as we
routinely obtained 30–70𝜇g of purified DIII from 1 g of N.
benthamiana leaves with 30–50% recovery rate in pilot scale
experiments (Chen, unpublished data). The underestimation
could be partially attributed to the fact that hE16 was used
as a capture antibody in the ELISA, as it only detected
fully folded DIII that displayed the specific conformational
epitope. Regardless, this expression level of WNVDIII is still
the highest compared with other plant-produced Flavivirus
vaccine proteins, including DIII of dengue virus expressed
with a TMV-based vector in tobacco [36]. Since the pro-
duction of DIII was performed under standard conditions,
its accumulation level in plants can be further increased by
genetic and environmental optimizations.
Production of DIII by using plant-expression systems
may also overcome the challenge of limited scalability and
cost issues associated with bacterial and insect cell culture
6 BioMed Research International
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Figure 6: Binding of antibodies in anti-DlII serum to DIII displayed on yeast cell surface. DIII displaying yeast cells were incubated with
pooled sera collected on week 11 from mice injected with either 25 𝜇g of plant-produced DIII (a) or PBS (b). hE16 was used as a positive
control mAb (c). After incubation, yeast cells were stained with an Alexa Fluor 488-conjugated goat anti-mouse (a and b) or goat anti-human
(c) secondary antibody and processed by flow cytometry.
systems. The scalability of both upstream and downstream
operations for transient plant expression systems has been
recently demonstrated. For example, we used nontransgenic
N. benthamiana plants for DIII production in this study.
As a result, the wild-type plant biomass can be cultivated
and produced in large scale with routine agriculture practice
without the need to build extraordinarily expensive cell
culture facilities [23, 37–39]. We previously demonstrated
that commercially produced lettuce could be used as an
inexpensive and virtually unlimited source for pharmaceuti-
cal protein production [40]. Accordingly, the agroinfiltration
process to deliver DIII DNA construct into plant cells has
been automated and can be operated in very large scales. For
example, several metric tons of N. benthamiana plants are
regularly agroinfiltrated per hour by using a vacuum infil-
tration procedure [27, 28]. For downstream processing, our
extraction and purification procedure eliminated the hard-
to-scale up steps of denaturing and refolding and allowed
the recovery of highly purified DIII with a simple two-step
procedure of low pH precipitation and IMAC.The scalability
of the downstream process, consisting of precipitation and
affinity chromatography, has been extensively demonstrated
by the pharmaceutical industry and by our studies with other
plant-produced biologics [30, 41]. This simple and scalable
downstream process from plants will also reduce the costs
associated with denaturing and refolding procedures and the
overall cost for DIII production. The cost-saving benefit of
plant-expression systemswas also extensively documented by
several case studies.
Our results also indicated that plant-produced DIII
showed at least equivalent potency in eliciting humoral
response against WNV in mice as E. coli-produced DIII. The
demonstration of antibodies in anti-plant DIII serum that
competed with hE16 for the same DIII epitope indicates the
induction of potentially protective antibodies against WNV.
It is interesting that both plant- and E. coli-produced DIII
evoked a Th2-type response with alum as the adjuvant. This
is in contrast to a previous report that E. coli DIII with CpG
adjuvant stimulated a Th1-biased response [33]. This is not
totally unexpected, as comparative studies with Flavivirus
antigens showed that alum tends to induceTh2 type response,
while CpG is likely to skew the response toward the Th1
type [42]. Since E. coli-produced DIII was shown to be
protective in the mouse challenge model [29, 33, 34], the
equivalent potency of plant-DIII in generating high IgG titers
and the induction of hE16-like antibodies suggest that it is
highly likely that plant-DIII will induce protective immunity
when a proper adjuvant is used. Overall, the rapidity of DIII
expression, the availability of a simple purification scheme,
and the low risk of contamination by human pathogen and
endotoxin indicate that plants provide a robust and low-
cost system for commercial production of subunit vaccines
against WNV and other flaviviruses.
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Figure 7: Competitive ELISA of DIII binding by hE16 and antibod-
ies in anti-DIII serum. Plant-derivedDIII immobilized inmicrotiter
plate wells was preincubated with 1 : 100 dilution of indicated sera.
hE16 was then applied to sample wells to determine its binding to
DIII.The inhibition of serum preincubation on the subsequent hE16
binding to DIII is presented as the % of OD
450
reduction by the
preincubation. Mean ± SD of samples from three measurements is
presented.
4. Experimental Procedures
4.1. Construction of DIII Expression Vectors. The coding
sequence of WNV E DIII (amino acid 296–415, Genbank
Acc. number AF196835) was synthesized with optimized N.
benthamiana codons [43]. An 18 bp sequence coding for the
hexa-histidine tag (His
6
) was added to the 3󸀠 terminus of the
DIII gene and then cloned into the TMV-based expression
vector pIC11599 of the MagnICON system [30, 43]. The
MagnICON vectors were chosen because they have been
demonstrated to drive high-level accumulation of recombi-
nant proteins in N. benthamiana plants [30, 31, 38, 41, 43].
4.2. Expression of WNV E DIII in N. benthamiana Leaves.
Plant expression vectors were transformed into A. tume-
faciens GV3101 by electroporation as previously described
[24]. N. benthamiana plants were grown and agroinfiltrated
or coagroinfiltrated with the GV3101 strain containing the
DIII-His
6
3󸀠 module (pICH11599-DIII) along with one of
its respective 5󸀠 modules (pICH15579 for cytosol targeting,
pICH20999 for ER targeting, or pICH20030 for chloro-
plast targeting) and an integrase construct (pICH14011) as
described previously [27, 28, 30, 38, 41].
4.3. Extraction and Purification of DIII from N. benthami-
ana Leaves. Agroinfiltrated N. benthamiana leaves were
harvested 2–5 dpi for evaluating DIII expression. Leaves
were harvested 4 dpi for other protein analysis. Leaves were
homogenized in extraction buffer (100mMTris-HCl, pH 8.0,
150mMNaCL, 1mMPMSF, tablet protease inhibitor cocktail
(Sigma, Germany) at 1mL/g LFW). The extract was clarified
by centrifugation at 18,000×g for 30min at 4∘C. The pH
of the clarified extract was adjusted to 5.0 and subjected to
centrifugation at 18,000×g for 30min at 4∘C.The supernatant
was recovered, pH adjusted back to 8.0, and subjected to
another centrifugation. The supernatant was then subjected
to Ni IMAC on a 4mL His. Bind column in accordance with
themanufacturer’s instruction (Millipore, USA).The purified
WNV DIII was eluted with imidazole and the eluate was
dialyzed against PBS. The purity of DIII was estimated by
quantitating Coomassie blue-stained protein bands on SDS-
PAGE using a densitometer as described previously [30].
4.4. SDS-PAGE, Western Blot, and ELISAs. Samples contain-
ing DIII were subjected to 15% SDS-PAGE under reducing
(5% v/v 𝛽-mercaptoethanol) conditions. Gels were either
stained with Coomassie blue or used to transfer proteins
onto PVDF membranes (Millipore, USA). Membranes were
first incubated with MAb hE16 [30] and then subsequently
with a goat anti-human kappa antibody conjugated with
horseradish peroxidase (HRP) (Southern Biotech). Specific
bindings were detected using an “ECL plus” Western blot
detection system (Amersham Biosciences).
The expression of WNV DIII protein in leaves was
determined by a sandwich ELISA. Ninety-six well ELISA
microtiter plates (Corning Incorporated, USA) were coated
at 1 𝜇g/mL hE16 mAb in coating buffer (100mM Na
2
CO
3
,
pH 9.6) overnight at 4∘C. After washing three times with
PBST (PBS containing 0.1% Tween-20), plates were blocked
with blocking buffer (PBS containing 5%milk) and incubated
with plant extracts. Purified bacterial WNV DIII was used
as a positive control to generate the standard curve. Extracts
from uninfiltrated plants were used as a negative control.
After washing, the plate was incubated with a rabbit anti-
WNV DIII polyclonal antibody [43], followed by an HRP-
conjugated goat anti-rabbit IgG (Southern Biotech). The
plates were then developed with TMB substrate (KPL Inc).
Values from negative control leaves were used as “back-
ground” of the assay and were subtracted from the cor-
responding values obtained from DIII construct-infiltrated
leaves.
The hE16 recognition ELISA was performed as described
previously [30]. Briefly, purified plant-DIII was immobilized
on microtiter plates. After incubation with hE16 purified
from mammalian cells or from plants, an HRP-conjugated
goat anti-human-gamma HC antibody (Southern Biotech)
was used to detect bound antibodies. A generic human IgG
(Southern Biotech) was used as a negative control.
The titer of DIII-specific IgG in mouse serum was also
determined by an ELISA. Microtiter plates were coated with
plant- or E. coli-derived DIII, blocked with PBS with 1%
bovine serum albumin (BSA), and incubated with a serial
dilution of serum. After washing with PBST, the plates were
incubated with an HRP-conjugated goat anti-mouse IgG
(H+L) (Southern Biotech). After further washingwith PBST,
the plates were developed with TMB substrate (KPL Inc).
Geometric mean titer (GMT) was calculated for each group
at various time points and was used to express the titer of the
DIII specific IgG.
The ELISA for determining the IgG1 and IgG2a subtypes
were performed also on plates coated with plant- or E. coli-
derived DIII as described above. Serial dilutions of serum
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were applied to sample wells and incubated for 2 hr at 37∘C.
After washing with PBST, the plates were incubated with an
HRP-conjugated goat anti-mouse IgG1 (Santa Cruz Biotech)
or anti-mouse IgG2a (Southern Biotech). In parallel, various
dilutions of mouse IgG1 and IgG2a (Southern Biotech) were
coated on the same set of plates for generating standard
curves. The plates were developed with TMB substrate (KPL
Inc.).
A competitive ELISAwas also performed on plates coated
with DIII purified from plants. After blocking, plates were
preincubated with serial dilutions of serum from pooled
preimmune serum (Group 3), or pooled serum collected
at week 11 (Groups 1 and 3). After thorough washing
with PBST, plates were incubated with hE16, subsequently
an HRP-conjugated goat anti-human-gamma HC antibody
(Southern Biotech), and developed with TMB substrate (KPL
Inc). The inhibition of hE16 binding to DIII by preincu-
bation of sera was calculated by (Binding
(no pre-incubation) −
Binding
(pre-incubation with serum)) /Binding(no pre-incubation).
All ELISA measurements were repeated at least three
times with each sample in triplicate.
4.5. DIII Expression in E. coli and Yeast Surface Display.
The synthesized DIII coding sequence was cloned into the
pET28a bacterial expression plasmid (EMD Milipore) with
EcoRI and HindIII sites. DIII was expressed in E. coli and
purified using an oxidative refolding protocol as described
previously [44]. Refolded DIII protein was further purified
with aNiHis. Bind IMACas described for plant-derivedDIII.
Yeast expressing WNV DIII was generated and stained
with mAbs as described previously [30]. Briefly, yeast cells
were first grown to log phase and subsequently induced for
DIII expression by an additional 24 h culture in tryptophan-
free media containing 2% galactose. The yeast cells were
then incubated with pooled mice serum collected in week
11 from the DIII immunization experiments or hE16 mAb
as a positive control [30]. Serum from the saline mock-
immunized mice was used as a negative control. The yeast
cells were stained with a goat anti-mouse or goat anti-
human secondary antibody conjugated with Alexa Fluor 488
(Invitrogen). Subsequently, the yeast cells were analyzed on a
BD FACSCalibur flow cytometer (Franklin Lakes).
4.6. Mouse Immunization. All animal work was approved by
the institutional animal care and use committee. Five-week
old female BALB/C mice were divided into 5 groups (𝑛 = 6
per group). Group 1 received saline buffer (PBS) with alum as
mock immunized control. Groups 2 and 3 received 5𝜇g and
25 𝜇g of plant-derived DIII per dosage, respectively. Groups
4 and 5 received 5 𝜇g and 25 𝜇g of E. coli-produced DIII
per dosage as controls. On day 0, each mouse was injected
subcutaneously with 100 𝜇L of material containing saline
(Group 1), 5 𝜇g (Groups 2 and 4), or 25 𝜇g (Groups 3 and 5)
purified DIII protein in PBS with alum as adjuvant (Sigma,
DIII Protein solution: alum volume ratio = 1 : 1). Mice were
boosted three times (on days 21, 42, and 63) with the same
dosage and immune protocol as in the 1st immunization.
Blood samples were collected from the retroorbital vein on
day 0 before the immunization (pre-immune sample) and on
days 14 (2 week), 35 (5 week), 56 (8 week), and 77 (11 week)
after the 1st immunization. Serum was stored at −80∘C until
usage.
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